Chapter 7
Researchers are studying medications that target three metabolic pathways at once. Here’s what’s investigational, what’s real, and what it means for the future of obesity care.
regulated medications
chapters in this guide
Physician-Reviewed
Medical Weight Loss Guide
KEY TAKEAWAY
The approval of Semaglutide marked a turning point in obesity medicine. Tirzepatide expanded that progress by activating two naturally occurring metabolic pathways instead of one. Today, researchers are exploring whether activating three complementary hormone pathways simultaneously may produce additional metabolic benefits — building upon, rather than replacing, earlier medications.
Retatrutide is an investigational medication currently being studied in clinical trials, designed to activate three metabolic pathways: GLP-1, GIP, and glucagon. Researchers are studying whether activating these pathways together may provide complementary metabolic effects. As of publication, Retatrutide remains investigational and has not been approved by the FDA — clinical trials are ongoing.
Many people associate glucagon only with blood sugar regulation. Researchers have also been studying its potential role in energy expenditure, fat metabolism, and metabolic flexibility. Scientists hope combining glucagon receptor activity with GLP-1 and GIP may create therapies that more closely mimic the body’s complex hormonal network — more research is still needed.
The future of obesity care is not only about newer drugs — it’s about better personalization. Future treatment plans may consider genetics, biomarkers, laboratory testing, body composition, sleep, stress, wearable data, and treatment response. Instead of asking “what medication treats obesity,” providers may increasingly ask “what treatment works best for this individual?”
Another exciting area of research involves oral formulations, since many patients prefer taking medication by mouth rather than using injections. Researchers continue developing newer oral GLP-1 therapies designed to improve convenience while maintaining effectiveness; several investigational medications remain in clinical development.
Modern obesity medicine extends beyond medication — mobile health apps, connected scales, laboratory integration, continuous glucose monitoring, wearable devices, AI-assisted education, and remote monitoring help patients stay engaged while giving providers additional information. Technology should enhance, not replace, the relationship between patients and clinicians.
Clinical Pearl
Myth vs. Fact
Myth: “The newest medication is always the best.”
Fact: The most appropriate treatment depends on an individual’s medical history, goals, preferences, response to therapy, and healthcare provider’s clinical judgment.
Myth: “Future technology will replace doctors.”
Fact: Technology can improve communication, monitoring, and education, but it is intended to support — not replace — the expertise of licensed healthcare professionals.
Research Spotlight
No. Retatrutide is an investigational medication that has not been approved by the FDA. Clinical trials are ongoing.
A medication designed to activate three metabolic pathways at once — GLP-1, GIP, and glucagon — rather than one or two.
No. Digital tools are designed to support — not replace — the relationship between patients and licensed healthcare providers.
Ongoing research helps scientists better understand how appetite and metabolism are regulated, which may lead to additional treatment options for appropriate patients in the future.
Scientific References
Disclaimers
